De novo epigenetic changes at histone and DNA level that affect gene transcription in cancer may be less random than we originally thought. Leukemia fusion proteins associated with specific chromosome translocations could mechanistically determine the epigenetic fate of specific target genes critical for normal hematopoiesis. This seems to be the case with AML1-MTG16, a fusion protein resulting from the t(16;21) translocation, a hallmark of therapy-related leukemia and myelodysplastic syndrome. Here we show that AML1-MTG16 blocks both myeloid differentiation and proliferation in the 32D/WT1-mouse myeloid cell line. These biological effects can be traced to the AML1 and MTG16 moieties of the fusion protein, respectively. Further, we show that AML1-MTG16 can induce epigenetic repressive changes at the histone and DNA level of the AML1 target gene Csf1r (c-fms), encoding the macrophage colony stimulating factor receptor. We observed that, concomitant with Csf1r downregulation, 32D/WT1 cells lost the ability to undergo myeloid differentiation in response to the granulocyte macrophage colony-stimulating factor (GM-CSF). Thus, there seems to be an association between AML1-MTG16-induced myeloid maturation block and epigenetic changes of a myeloid master gene.
Introduction
Chromosome abnormalities affecting transcription factors or chromatin-modifying proteins in cancer cells can help to establish whether specific genetic changes are associated with specific epigenetic changes that may be relevant to leukemogenesis (Di Croce et al., 2002) . Here we show that this can be the case for the AML1-MTG16 fusion protein consequent to the translocation t(16;21), frequently associated with therapy-related leukemia and myelodysplastic disorders (Gamou et al., 1998) . AML1-MTG16 derives from the fusion of the acute myeloid leukemia 1 gene, AML1, which encodes the a subunit of the core-binding factor (CBF), on chromosome 21 (Miyoshi et al., 1991) , and the myeloid translocated gene on chromosome 16 (MTG16) (Gamou et al., 1998) . Specifically, the N-terminal portion of AML1, containing the DNA binding domain, is juxtaposed to an almost entire MTG16, leading to a protein very similar to the fusion protein AML1-MTG8 (AML1-ETO), characteristic of t(8;21)-positive acute myeloid leukemia (Erickson et al., 1992; Nisson et al., 1992; Kozu et al., 1993) .
Both MTG16 and MTG8 can recruit histone deacetylases (HDACs) (Rossetti et al., 2004, and references within) . Thus, the fusion of either one of the MTG moieties with the N-terminus of the AML1 transcription factor, which recognizes the TG(T/C)GGT motif (Meyers et al., 1993) , leads to repressive histone changes of the chromatin associated with AML1-target genes (Rossetti et al., 2004, and references within) . Indeed, treatment with an HDAC inhibitor was shown to relieve the repressive activity of AML1-MTG8 on a reporter gene driven by a promoter containing AML1 target sequences, thus indicating that this protein can induce histone deacetylation (Lutterbach et al., 1998) .
Here we show that introducing AML1-MTG16 into 32D/WT1 mouse myeloid cells leads to a block of myeloid maturation concomitant with repressive epigenetic downregulation of Csf1r/c-fms, which encodes the macrophage colony stimulation factor receptor. First, we found that AML1-MTG16 can adversely affect both G-CSF and GM-CSF-induced differentiation and cell growth. Deletion mutant analysis clearly linked this latter effect (unique for AML1-MTG16, but not AML1-MTG8) to the loss of the N-terminal MTG16 region. Further, by combining both a candidate and a global gene expression approach, we observed that the transcription of several endogenous genes containing AML1-binding sites was significantly lower in 32D/WT1 cells expressing AML1-MTG16. One of the transcriptionally repressed genes was Csf1r. Csf1r downregulation was associated with both aberrant histone hypoacetylation and de novo DNA methylation of the Csf1r regulatory regions. Of note, AML1-MTG16-positive 32D/WT1 cells carrying an epigenetically downregulated Csf1r were unable to differentiate into macrophages in response to GM-CSF. The exact contribution of Csf1r epigenetic downregulation to the myeloid maturation block induced by AML1-MTG16 remains to be established.
Results

AML1-MTG16 impairs both G-CSF-induced differentiation and proliferation in 32D cells
To test the effects of AML1-MTG16 on myelogenesis, we infected 32D/WT1 mouse myeloblasts, ectopically expressing human G-CSF receptor, with the retroviral vector pLNCX2 containing the AML1-MTG16 cDNA. Positive clones were isolated by using limiting dilutions and neomycin resistance selection in medium containing IL-3. Clonal cell populations were screened for AML1-MTG16 transcription by RT-PCR (data not shown). IC with an anti-MTG16 antibody (AB-16) showed expression of AML1-MTG16 protein in the positive clones (Figure 1d , left). Five clones expressing the exogenous protein at IC analysis and five clones carrying the empty retroviral vector were selected for further experiments. Both control clones and AML1-MTG16-positive clones did not show morphological differentiation when grown in the presence of IL-3 ( Figure 1a , left panels). Replacement of IL-3 with G-CSF induced control clones to differentiate over time into granulocytes (Figure 1a , right panels). In contrast, AML1-MTG16-positive clones grown in the presence of G-CSF did not show evidence of granulocytic differentiation in the majority of cells (Figure 1a , right panels). Real-time RT-PCR using Mpo-specific primers showed that lack of differentiation was paralleled by significantly lower levels of myeloperoxidase transcript (Mpo), a marker of myeloid differentiation, in AML1-MTG16-positive clones relative to control clones (Figure 1b) . AML1-MTG16-positive clones were significantly impaired in their proliferation ability, in contrast to control clones that proliferated up to 6 days, before progressively dying ( Figure 1c ). IC confirmed that AML1-MTG16 was still expressed during G-CSF treatment up to day 9 (Figure 1d , right). The growth inhibition induced by AML1-MTG16 was not among the biological effects induced by AML1-MTG8 in 32D cells (Ahn et al., 1998; Kohzaki et al., 1999) , strongly suggesting that the MTG16 moiety could be responsible for this effect. , were selected for subsequent analysis. When IL-3 was replaced by G-CSF, both MTG16-and MTG16D2-positive clones were able of granulocytic differentiation ( Figure 2b ). However, in the presence of G-CSF, MTG16D2 had a dominant negative effect on the endogenous MTG16, leading to growth-arrest ( Figure 2c ). This was not the case with the exogenous wild-type MTG16 (Figure 2c ). MTG16D2, like AML1-MTG16, induced growth-arrest in G0-G1, as determined by cytofluorimetric analysis (Figure 2d ), as well as apoptosis, as shown by the caspase-3 cleavage assay ( Figure 2e ). Thus, both the block of differentiation and the inhibition of cell proliferation by AML1-MTG16, can be traced to either the AML1 moiety or the MTG16 moiety (lacking the MTG16 N-terminus), respectively.
AML1-MTG16 induces downregulation of endogenous AML1-target genes
As mentioned, we previously found that AML1-MTG16 can interact with histone deacetylases (HDACs) (Hoogeveen et al., 2002) . This led us to hypothesize that AML1-MTG16 is capable of inducing epigenetic repression of endogenous AML1 target genes by tethering, via the MTG16 moiety, HDACs at AML1-target sites. By using both real-time RT-PCR with primers of known AML1-target genes and by comparing Affymetrix mouse microarrays (MOE 430A) probed with the RNA of either AML1-MTG16-positive 32D cells or control 32D cells, we found that several genes with one, or more, AML1 consensus sequence, were significantly downregulated in AML1-MTG16-positive cells (comprehensive list of genes to be published elsewhere). Among the transcriptionally downregulated genes we found Csf1r/c-fms, encoding the macrophage colonystimulating factor receptor. Csf1r transcription is regulated by a promoter, a putative enhancer and the FMS intronic regulatory element, FIRE, which contains a canonical AML1-binding site (Tagoh et al., 2002) (Figure 3a) . Both wild-type AML1 and AML1-MTG8 can bind CSF1R at AML1-binding sites (Zhang et al., 1994; Follows et al., 2003) . To test whether AML1-MTG16 can bind the Csf1r promoter, we performed ChIP with an antibody directed against the MTG16 moiety (Hoogeveen et al., 2002) , followed by quantitative amplification of the Csf1r FIRE region. A significant enrichment of FIRE DNA in the chromatin of AML1-MTG16-positive cells relative to the chromatin of control cells (Figure 3b ) proved that AML1-MTG16 can bind the endogenous Csf1r.
Comparison of Csf1r transcription levels of AML1-MTG16-positive and -negative cells showed significant transcriptional downregulation (P-valueso0.05) in AML1-MTG16-positive cells grown either with IL-3 or G-CSF (16 h, 48 h and 6 days) (Figure 3c ). These data could reflect epigenetic changes in the Csf1r regulatory regions.
AML1-MTG16 induces Csf1r histone hypoacetylation
Since we previously observed that AML1-MTG16 is capable of recruiting HDACs (Hoogeveen et al., 2002) , we hypothesized that Csf1r downregulation in AML1-MTG16-positive clones was associated with epigenetic histone changes. Of note, aberrant hypoacetylation of human CSF1R, highly homologous to mouse Csf1r, was shown to correlate with AML1-MTG8 downregulation in t(8;21)-positive leukemic cells, suggesting that AML1-MTG proteins exert an epigenetic constraint of CSF1R expression (Follows et al., 2003) . By using antibodies against acetylated histones H3 and H4 and ChIP, we quantified the histone acetylation level of the promoter, putative enhancer and FIRE regions as well as the acetylation level of two control arbitrary regions (at 2 kb upstream of the promoter and 10 kb downstream of the FIRE region, respectively) in both control and AML1-MTG16-positive 32D/WT1 cells (Figure 3a) . In the presence of IL-3, no significant difference could be detected between the histone acetylation level of control cells and AML1-MTG16-positive cells (Figure 4a ). In contrast, in AML1-MTG16-positive 32D/WT1 cells grown in G-CSF for 6 days (when Csf1r transcription was four times lower than in control cells, Figure 3a) , we observed significant hypoacetylation of histone H3 (Po0.05) (Figure 4a , left) and even more significant hypoacetylation of histone H4 (Po0.03) (Figure 4a, right) . Apparently, G-CSF induced significantly lower Csf1r histone acetylation in the presence of AML1-MTG16, which was reflected by Csf1r downregulation (Figure 3c ). Thus, AML1-MTG16 seemed capable of antagonizing the G-CSF transcriptional activation effect by inducing histone hypoacetylation.
De novo hypermethylation of the FIRE region in AML1-MTG16-positive cells Repressive histone modifications, including hypoacetylation, are often associated with aberrant DNA hypermethylation (Jaenisch and Bird, 2003) . The human CSF1R gene has been found to be aberrantly hypermethylated in leukemic cells (Felgner et al., 1991) . For this reason, we evaluated the DNA methylation status of the Csf1r FIRE region in AML1-MTG16-positive cells. By bisulfite sequencing we found that over 50% of the Csf1r alleles displayed de novo methylation in the CpG sites 7-10 of the Csf1r FIRE region (Figure 4b ). These CpG sites were aberrantly hypermethylated in AML1-MTG16-positive 32D/WT1 cells grown in either IL-3 or G-CSF (Figure 4b ). This finding showed an accumulation of repressive epigenetic changes at Csf1r in AML1-MTG16-positive 32D/WT1 cells.
Epigenetic Csf1r downregulation is paralleled by a block of macrophage differentiation
Csf1r is the receptor of the macrophage colonystimulating factor. We tested whether Csf1r transcriptional downregulation by AML1-MTG16 was associated with an altered 32D/WT1 macrophagic differentiation. AML1-MTG16-positive 32D/WT1 cells grown in the presence of granulocyte/macrophage colony-stimulating factor (GM-CSF) for 6 days failed to undergo macrophagic differentiation (Figure 4c ). Further mechanistic studies (e.g. Csf1r knockdown by RNA interference in 32D/WT1 cells) are required to establish at which extent Csf1r epigenetic downregulation can contribute to the observed block of macrophage differentiation.
Discussion
This study shows that AML1-MTG16, the product of the leukemia-associated translocation t(16;21), induces epigenetic downregulation of endogenous Csf1r in association with a block of myeloid maturation in the mouse 32D/WT1 myeloid cell line. 32D/WT1 cells stably expressing the AML1-MTG16 fusion protein are crippled in their ability to both proliferate and differentiate into granulocytes when grown in the presence of G-CSF (Figure 1) . Thus, the biological effect of AML1-MTG16 on 32D/WT1 cells partially differs from the effect of AML1-MTG8, which was shown to negatively affect only G-CSF-induced granulocyte differentiation, but not proliferation in 32D cells (Ahn et al., 1998; Kohzaki et al., 1999) . AML1-MTG16 differs structurally from AML1-MTG8 in the MTG moiety. When we tested whether this moiety was responsible for the dominant-negative effect on cell growth, we found that this was indeed the case. A deletion mutant, MTG16D2, lacking the N-terminal 127 amino acids of the wild-type MTG16, remarkably affected G-CSF-dependent proliferation of 32D/WT1 cells, similar to AML1-MTG16. The mechanism at the basis of this effect was traced to premature cell cycle arrest followed by apoptosis (Figure 2) . Apparently, loss of the N-terminus of MTG16 has profound biological consequences on myeloid cell growth. We previously hypothesized a critical role for the N-terminus of MTG16 based on the observation that exogenous MTG16D2 had a different intranuclear localization than exogenous MTG16 in COS cells (Hoogeveen et al., 2002) . However, we were unable to show different intranuclear localization for these two proteins in 32D/ WT1 cells. The effects on 32D/WT1 myeloid maturation by AML1-MTG16 suggest that similar negative effects on human myelogenesis by AML1-fusion proteins might contribute to malignant transformation.
We reported previously that AML1-MTG16 is an altered transcriptional corepressor capable of specifically recruiting HDACs (Hoogeveen et al., 2002) . We hypothesize that part of the AML1-MTG16-induced effects on 32D/WT1 myelogenesis could be the consequence of distinct epigenetic changes determined by the fusion protein. By gene expression analysis, we identified several endogenous AML1-target genes whose transcription was aberrantly repressed in AML1-MTG16-positive 32D/WT1 cells (data to be published elsewhere).
The transcription of Csf1r, encoding the macrophage colony-stimulating factor receptor, which is essential for macrophage maturation, was also significantly downregulated. We chose this gene, a master regulator of myeloid differentiation, to test for epigenetic changes, based on the evidence that AML1-fusion proteins can deregulate CSF1R transcription (Zent et al., 1996) . In particular, it has been shown that AML1-MTG8 binds directly and with high affinity the CSF1R promoter (Follows et al., 2003) . Besides, AML1-MTG8 silencing has been shown to be associated with upregulation of CSF1R protein in t(8;21)-positive cells (Heidenreich et al., 2003) , while the presence of AML1-MTG8 in leukemic cells has been reported to correlate with CSF1R downregulation (Follows et al., 2003) . We proved that in the 32D/WT1 model, AML1-MTG16 can bind to the endogenous Csf1r FIRE regulatory region in AML1-MTG16-positive cells, where Csf1r is significantly downregulated (Figure 3) . We further proved that Csf1r downregulation is associated with epigenetic changes at histone and DNA level. First, by chromatin immunoprecipitation we demonstrated significant Csf1r hypoacetylation in the FIRE region as well as the putative enhancer regions in AML1-MTG16-positive 32D cells (Figure 4) . Second, we detected de novo hypermethylation of specific CpG sites in the FIRE region, which has the highest level of histone H4 hypoacetylation. Of note, epigenetic downregulation of Csf1r in AML1-MTG16-positive 32D cells was paralleled by lack of response to the GM-CSF (Figure 4) . It remains to be mechanistically proven whether this biological effect is indeed consequent to the observed Csf1r epigenetic downregulation.
Different tumor types, including leukemia, seem to be characterized by distinct epigenetic profiles (Costello et al., 2000) . However, it is still debated whether de novo epigenetic changes at both histone and DNA level are random, or rather the consequence of upstream mutational events (Baylin and Bestor, 2002) . There is evidence that PML-RARA, the fusion protein associated with the t(15;17) translocation of acute promyelocytic leukemia, can induce aberrant hypermethylation of a retinoic acid receptor alpha (RAR alpha)-target gene in hematopoietic cells (Di Croce et al., 2002; Fazi et al., 2005) . Here we show that expression of AML1-MTG16, the fusion protein associated with the t(16;21)-positive myelogenous leukemia, can induce myeloid maturation block in association with Csf1r epigenetic downregulation.
Several AML1-target genes that are critical for definitive myelogenesis may be aberrantly regulated by AML1-MTG16. One of these genes could be C/EBP alpha, a master myeloid gene that cooperates with AML1 in the regulation of Csf1r . Interestingly, AML1-MTG8 seems to indirectly downregulate C/EBP alpha expression (Pabst et al., 2001 ). However, we were unable to detect any significant change in the transcription level of endogenous C/EBP alpha in AML1-MTG16-positive 32D/WT1 cells (unpublished observations). So far, by global gene expression analysis, we have found that the transcription of at least 35 genes is significantly downregulated in AML1-MTG16-positive 32D clones relative to control clones. About half of these downregulated genes, some of which were involved in functions as diverse as transcription regulation, signaling and cell proliferation, contained one, or more, AML1 consensus sequence. We are currently investigating both histones and DNA modifications in the regulatory regions of these genes by using a systematic approach like the one we described for Csf1r. The development of integrated systems for the simultaneous assessment of both gene expression and chromatin changes (Shi et al., 2003) could facilitate the analysis of multiple epigenomic changes. Ultimately, comparison of global epigenomics profiles might reveal why leukemia subtypes carrying similar mutant proteins like AML1-MTG16 and AML1-MTG8 develop different phenotypes.
Materials and methods
Cell culture
The mouse myeloid cell line 32D/WT1, ectopically expressing human granulocyte colony stimulating factor (G-CSF) (de Koning et al., 1998) , was maintained in the presence of 10 ng/ ml of murine interleukin-3 (IL3) (BD Biosciences, San Jose, CA, USA) in RPMI 1640 medium supplemented with 10% fetal calf serum, 1% antibiotics (penicillin/streptomycin), adjusting the cell density to 2 Â 10 5 cells/ml daily. To induce granulocyte differentiation, cells were washed in RPMI medium, and IL-3 was replaced with 10 ng/ml human G-CSF (Amgen, Thousand Oaks, CA, USA). Viable cells were counted daily to determine the growth curve. Granulocyte/ macrophage differentiation was induced by replacing IL-3 with 10 ng/ml GM-CSF (Peprotech, Rocky Hill, NJ, USA). Differentiation was microscopically evaluated on cytospin preparations stained with May-Gru¨nwald-Giemsa.
Retroviral infections
Human MTG16a, AML1-MTG16 type 1 and MTG16D2 cDNAs were subcloned into the retroviral expression vector pLNCX2 (Clontech, Palo Alto, CA, USA) starting from pBluescript-MTG16a (kindly provided by Drs Kosoda and Okhi, Tokyo, Japan), pLNSX-AML1-MTG16 type 1 (kindly provided by Dr I Kitabayashi, Tokyo, Japan) and pcDNA3.1-MTG16D2 (Hoogeveen et al., 2002) , respectively. Retroviral viruses from empty pLNCX2, pLNCX2-MTG16a, pLNCX2-AML1-MTG16 or pLNCX2-MTG16D2 were produced in Phoenix amphotropic cells and used for infecting 32D/WT1 cells grown on dishes coated with retronectin (12 mg/ml) (Takara Bio Inc., Otsu, Japan). Infected cells were selected with 0.8 mg/ml G 418 sulfate (Calbiochem, La Jolla, CA, USA); single clones were isolated by limiting dilution. Clones were screened for the presence of the desired construct by both polymerase chain reaction (PCR) and immunocytochemistry (IC) according to standard procedures. A polyclonal rabbit antibody against MTG16 (AB-16) (Hoogeveen et al., 2002) and a TRITC-conjugated anti-rabbit secondary antibody (Sigma, St Luis, MO, USA) were used to detect both MTG16 (full length and deletion mutant) and AML1-MTG16. Nuclei were stained with DAPI. Images were acquired with a fluorescence microscope (Axioplan 2, Zeiss, Germany). A minimum of five clones for each construct were selected and used for subsequent analyses.
Cell cycle and apoptosis analysis 32D/WT1 cells infected with different constructs, and at different stages of differentiation, were fixed in cold methanol at À201C for 30 0 , washed twice in PBS þ 0.5 % BSA, stained with 50 mg/ml propidium iodide (PI) and run through a flow cytometer (FACScalibur System, BD Biosciences, San Jose, CA, USA). Cell cycle was analysed with ModFitLT V2.0. Western blotting and an antibody directed against cleaved caspase-3 (1 : 1000, Cell Signaling Technology, Beverly, MA, USA) were used to detect apoptosis.
Primers, RT-PCR and real-time RT-PCR
Total RNA was extracted with RNeasy mini kit (Qiagen, Hilden, Germany) and treated with DNase (Qiagen). The RNA was then reverse transcribed using Super Script FirstStrand Synthesis System (Invitrogen, Carlsbad, CA, USA) and amplified by standard or quantitative PCR. Quantitative realtime PCR was performed on iCycler (Bio-Rad, Hercules, CA, USA) using qPCR Core Kit for SYBR Green (Eurogentec, Seraing, Belgium). The following forward (fwd.) and reverse (rev.) primers were used: mMTG8: fwd. 5
0 . The transcription levels of the different genes were normalized to mouse Gapdh. The data represent the trimmed mean of four independent experiments performed in triplicate on two control clones and two AML1-MTG16-positive clones. Significance was determined using the Student's t-test.
Chromatin immunoprecipitation (ChIP)
ChIP was performed using protocol and reagents purchased from Upstate (Charlottesville, VA, USA). Chromatin was immunoprecipitated by using antiacetylated H3 (1 : 200, Upstate), antiacetylated H4 (1 : 200, Upstate) or anti-MTG16 (AB-16, 1 : 100) (Hoogeveen et al., 2002) . Control ChIP was performed without antibody. The immunoprecipitated DNA was amplified by real-time PCR on iCycler (Bio-Rad) using qPCR Core Kit for Sybr Green (Eurogentec) and the following specific forward and reverse primer sets for different regions of the Csf1r locus: PromoterÀ2 kb: fwd. 5 0 -GCAACACATGC ATGAGGTTCTG-3 0 , rev. 5 0 -CTCTTCACATGAGTGGCT AG-3 0 ; promoter: fwd. 5 0 -GAAGAGGAGCCAGTGCAAC AG-3 0 , rev. 5 0 -GATAGCGTGAGCCGATGCAG-3 0 ; putative enhancer: fwd. 5 0 -GCGAGATGAACAATGGCCAGG-3 0 , rev. 5 0 -CAGAACAGGGCTGACGAATTC-3 0 ; FIRE: fwd. 5 0 -GA GGCTGTGAATCAGTTCTCAC-3 0 , rev. 5 0 -TCGCTTCTCT GAGCCTGCTG-3 0 ; FIRE þ 10 kb: fwd. 5 0 -CAGAGAGTGC CTACTTAAACTTG-3 0 , rev. 5 0 -CTCAAGCTTGCGCTGGT CTTC-3 0 . The data were normalized to the input DNA and to a region 10 kb downstream from the FIRE regulatory region. Similar results were obtained by normalizing the data to the housekeeping gene encoding for histone H4. Significance was determined using the Student's t-test.
Bisulfite sequencing
Genomic DNA was extracted with DNAzol (Invitrogen), according to the manufacturer's instructions. DNA was modified by sodium bisulfite treatment as previously described (Herman et al., 1996) . The FIRE region of Csf1r was amplified by semi-nested PCR first with primers P14 (5 0 -GAAGGA TAATGGTTAGGAGGTT-3 0 ) and P16 (5 0 -AATCTTCCAA ATATCTCCTACTA-3 0 ), then with primers P15 (5 0 -TAAG TGTTGAAGGGTTATAGGT-3 0 ) and P16 (see Figure 3) . The PCR fragments were sequenced directly three times with primers P15 and P16. The results from the direct sequencing were confirmed by subcloning the PCR fragments into pGEM-T (Promega, San Luis Obispo, CA, USA) and sequencing of 20 clones for each PCR fragment.
